Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced the grand opening of its state-of-the-art TIL manufacturing facility located at Anting International Medical Industry Park in Jiading District, Shanghai, China. This facility has the largest capacity and was constructed in compliance with the highest standards.
Juncell Therapeutics' state-of-the-art facility, with a total area exceeding 16,000 square meters, houses the company's production center, quality center, data center, and operation center. This facility, with a designed production capacity of TIL products for 6,000-10,000 patients annually, represents another significant milestone following the approval of GC101, the world's first IL-2-administration-free natural TIL therapy with a low-intensity pretreatment, to enter the pivotal Phase II clinical trial. The establishment of this facility will significantly promote the development of high-quality TIL products and the transformation of disruptive technologies into new quality productive forces.
Dr. Jin Huajun, the founder of Juncell Therapeutics, expressed his heartfelt gratitude to all the leaders and guests present at the ceremony. He stated that the company was founded and grew in Jiading, received care and support from the government and partners. Currently, GC101, the world's first IL-2-administration-free natural TIL therapy, has entered the pivotal Phase II clinical trial and is expected to be launched in 2026. The first-in-class non-viral gene-modified TIL therapy GC203 has entered Phase I clinical trial and is anticipated to be launched in 2027. The two products have demonstrated excellent clinical efficacy and safety. Committed to its mission of "Rebuild cells, Rescue lives", the company will deliver safe, competent, affordable and high-quality TIL therapies to patients.
Comments powered by CComment